多西紫杉醇联合PF方案治疗晚期食管癌疗效观察  

Clinical Study of Docetaxel Combined with Cisplatin and Fluorouracil in Treatment of Advanced Esophageal Cancer

作　　者：黄承锁[1] 王哲海[1] 陈阵[1] 

机构地区：[1]山东省肿瘤医院内三科,济南250017

出　　处：《肿瘤防治研究》2008年第6期436-438,共3页Cancer Research on Prevention and Treatment

摘　　要：目的观察多西紫杉醇（TXT）联合PF方案治疗晚期食管癌的疗效和可行性。方法60例晚期食管癌按入院先后顺序随机分为治疗组32例，对照组28例，治疗组：TXT75mg／m^2，第1天，DDP35mg／m2，第1、2天，CF0．2g，第1～5天，静脉滴注，5-Fu2．5g／m^2持续泵入120h；对照组：仅含DDP、5-Fu、CF，用法同治疗组，21天为一周期，连用两周期以上。结果治疗组CR率为6．25％，RR为71．9％，对照组CR率为3．57％，RR为42．9％，两组CR率差异无统计学意义（P〉0．05），RR差异有统计学意义（P=0．044），治疗组初治患者RR为73.6％。复治患者RR为69．2％，差异无统计学意义（P〉0．05）。治疗组白细胞减少发生率高于对照组，但差异未见统计学意义，脱发发生率明显高于对照组（P=0．000）。结论多西紫杉醇（TXT）联合PF方案治疗晚期食管癌RR明显提高，毒副反应略有增加，但能耐受。Objective To evaluate the efficiency and feasibility of combination chemotherapy with docetaxel（TXT） plus PF regimen in the treatment of advanced esophageal cancer. Methods Sixty patients with advanced esophageal cancer were enrolled and randomly divided into treatment group （32 cases） and control group （28 cases）. Treatment group TXT 75mg/m^2 , on d1, Cisplatin 35mg/m^2 , on d1-2, CF 0. 2 g, on d1-5, and 5-Fu 2.5g/m^2continuous infusion in 120 hours, with 21 days one cycle for 2 cycles at least; Control group： Cisplatin,5-fluorouracil,CF, the same to treatment group but with no use of TXT; with 21 days one cycle for 2 cycles at least. Results The CR rate of treatment group was 6. 25 % and RR rate was 71.9% with 3.57% and 42. 9% respect in the control group. The CR rate improved but with no significant difference （P〉0. 05）, and RR rate showed significant difference （P = 0. 044）. Within treatment group,the newly diagnosed subgroup got a RR rate of 73. 6%, showing no significant difference with 69. 2% of retreated patients. The leukopenia incidence of treatment group was a little higher（P〉 0. 05） , but the incidence of hair loss was significantly higher （P = 0. 000）. Conclusion Docetaxel （TXT） combined with PF can improve the RR rate of advanced esophageal cancer markedly with tolerated toxicity.

关 键 词：多西紫杉醇 PF方案 化疗 晚期食管癌 

分 类 号：R730.53[医药卫生—肿瘤] R735.1[医药卫生—临床医学]